New JV from upstart biotechs Pyxis, Alloy aims for rapid drug development in cancer, autoimmune diseases

Pyxis Oncology has plenty to do with three antibody-drug conjugates in the pipeline, so the upstart biotech has formed a new joint venture called Kyma Therapeutics with Alloy Therapeutics to develop even more targets in cancer and autoimmune diseases.